
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Permanent cosmetics, which are essentially tattoos, are causing some concern because of mistakes that are difficult to fix.